𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immunoadhesins as research tools and therapeutic agents

✍ Scribed by Avi Ashkenazi; Steven M Chamow

Publisher
Elsevier Science
Year
1997
Tongue
English
Weight
494 KB
Volume
9
Category
Article
ISSN
0952-7915

No coin nor oath required. For personal study only.

✦ Synopsis

An immunoadhesin is a fusion protein that combines the target-binding region of a receptor, an adhesion molecule, a ligand, or an enzyme, with the Fc region of an Ig. Immunoadhesins provide a unique tool for identifying unknown binding targets and for elucidating molecular interactions that control biological function. Recent studies suggest that immunoadhesins also may be useful therapeutically, as inhibitors of autoimmune and inflammatory diseases.

📜 SIMILAR VOLUMES

Antisense oligonucleotides as therapeuti
Antisense oligonucleotides as therapeutic agents
✍ Umberto Galderisi; Antonino Cascino; Antonio Giordano 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB

Antisense oligonucleotides can block the expression of specific target genes involved in the development of human diseases. Therapeutic applications of antisense techniques are currently under investigation in many different fields. The use of antisense molecules to modify gene expression is variabl

Nucleosides and Nucleotides as Potential
Nucleosides and Nucleotides as Potential Therapeutic Agents
✍ Dr. T. Y. Shen 📂 Article 📅 1970 🏛 John Wiley and Sons 🌐 English ⚖ 966 KB

## Abstract The present article summarizes recent progress in the study of nucleoside derivatives as antiviral and immunosuppressive agents. A number of 5′‐substituted 5′‐deoxy nucleosides have been found to be permeable and nonincorporable antimetabolites of 5′‐nucleotides. N^6^‐isopentenyladenosi

Immune cells as anti-cancer therapeutic
Immune cells as anti-cancer therapeutic targets and tools
✍ Magnus Johansson; Tingting Tan; Karin E. de Visser; Lisa M. Coussens 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

## Abstract Chronic inflammation is a contributing factor to overall cancer risk as well as cancer promotion and progression; however, pathways regulating onset of cancer‐promoting inflammatory responses are still poorly understood. Clinical data suggest that deficient anti‐tumor cell‐mediated immu